All In Biotech

NDA 211844 · Inforlife

Midazolam In 0.9% Sodium Chloride

Midazolam · Intravenous · Benzodiazepine

Last checked: Nov 19, 2026Latest source record: Jul 18, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Mar 22, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,448

153 Phase 3, 96 recruiting

FAERS reports

24,486

22,911 serious, 4,732 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: PERSONNEL AND EQUIPMENT FOR MONITORING AND RESUSCITATION, AND RISKS FROM CONCOMITANT USE WITH OPIOID ANALGESICS AND OTHER SEDATIVE-HYPNOTICS Personnel and Equipment for Monitoring and ResuscitationOnly personnel trained in the administration of procedural sedation, and not involved in the conduct of the diagnostic or therapeutic procedure, should administer Midazolam in 0.9% Sodium Chloride Injection [see Dosage and Administration (2.1), Warnings and Precautions (5.1)].Administering personnel must be trained in the detection and management of airway obstruction, hypoventilation, and apnea, including the maintenance of a patent airway, supportive ventilation, and cardiovascular resuscitation [see Dosage and Administration (2.1), Warnings and Precautions (5.1)].Resuscitative drugs, and age- and size-appropriate equipment for bag/valve/mask assisted ventilation must be immediately...

What it is approved for

From the label in effect Jul 31, 2025.

Midazolam in 0.9% Sodium Chloride Injection is indicated: • Continuous intravenous infusion for sedation of intubated and mechanically ventilated adult, pediatric, and neonatal patients as a component of anesthesia or during treatment in a critical care setting. Midazolam in 0.9% Sodium Chloride Injection is a benzodiazepine indicated for: • continuous intravenous infusion for sedation of intubated and mechanically ventilated adult, pediatric, and neonatal patients as a component of anesthesia or during treatment in a critical care setting. ( 1 )

Mechanism: Midazolam is a short-acting benzodiazepine central nervous system (CNS) depressant.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 22, 2021 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
2 products under this application
  • MIDAZOLAM IN 0.9% SODIUM CHLORIDE · MIDAZOLAM 100MG/100ML (1MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • MIDAZOLAM IN 0.9% SODIUM CHLORIDE · MIDAZOLAM 50MG/50ML (1MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Midazolam" as an intervention, any sponsor and status, largest first.

All 1,448 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective3,116
  • off label use2,383
  • hypotension1,390
  • drug interaction1,144
  • seizure1,077
  • acute kidney injury894
  • toxicity to various agents878
  • cardiac arrest851
  • pyrexia839
  • death681
  • status epilepticus649
  • condition aggravated645

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200458
2005155
2006119
200725
200832
200942
2010110
2011321
2012723
2013724
2014814
20151,068
20161,172
20171,339
20181,685
20191,932
20202,203
20212,491
20221,872
20232,143
20242,010
20252,152
20261,296

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 2, 2026

    Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-610-10). Please check wholesalers and distributors for inventory.

  • Current · updated Nov 2, 2026

    Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-611-10). Please check wholesalers and distributors for inventory.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,612 on PubMed

Sponsor: Inforlife

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.